CLINICAL SCIENCE-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=944268, encodeId=a40894426863, content=稿件号0076，under peer review40天了还没消息，有必要催一下不，好捉急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210411/da80771de7994056b41a9cf7d83c2962/5ab66ed7d0ad45638a7838a3990b1120.jpg, createdBy=97072405099, createdName=12362864m67暂无昵称, createdTime=Sun Feb 28 20:51:46 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=979002, encodeId=2c789e9002f2, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：前后经历拒稿重投，一审大修，一共160天，刚接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210411/da80771de7994056b41a9cf7d83c2962/5ab66ed7d0ad45638a7838a3990b1120.jpg, createdBy=97072405099, createdName=12362864m67暂无昵称, createdTime=Fri Jul 02 13:54:12 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903765, encodeId=fab8903e6588, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：Current Stage: In review，具体的stage: manuscript rejected，然后紧接着是in review，under peer revie一共50天，邮件目前还没发来，我想看看具体意见，一般要等几天啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10831618640, createdName=ygbn2003, createdTime=Tue Dec 01 09:15:47 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567729, encodeId=d14d56e729ba, content=后来送审没？zcxzcx 2016-04-30 21:05:00 发表: 我投了一篇，两天后给邮件说送同行评议，4周内给答复。5天后又成了副编辑审稿了。估计没有送审。不可能中的了。, beContent=zcxzcx 2016-04-30 21:05:00 发表: 我投了一篇，两天后给邮件说送同行评议，4周内给答复。5天后又成了副编辑审稿了。估计没有送审。不可能中的了。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22631703971, createdName=锦参, createdTime=Thu Mar 07 00:00:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801681, encodeId=d39580168137, content=投稿命中率:50.0 经验分享：杂志编辑友好，审稿人认真专业，一审周期1月，大修，二审周期1月，小修，三审半月，修回后接受，可选择OA或不OA。临床+基础+动物实验都有，同行评审的很专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=634, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12881707574, createdName=龙行, createdTime=Wed Jul 08 00:24:01 CST 2020, time=2020-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800767, encodeId=8ee1800e674f, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：看到大家都说很难中，就心惊胆战的投了稿。第一次投稿时，由于其中一个审稿人列出了很多意见，编辑让修改后重投，重新投稿后还是原来的审稿人审的，9天就审完了，给了小修意见，修改后再提交直接接收，一周内见刊。杂志对临床标本和动物造模的方法学要求很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/956562A6F0D877680D4FFBCDFE6C84CF/100, createdBy=40fb1970149, createdName=12.17, createdTime=Wed Jul 01 14:18:04 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574450, encodeId=91ae5e44501b, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：投过去十天左右送审，二十多天一审结束，一个reviewer几乎同意，一个大修，编辑给了大修意见，好多没法补实验，诚恳的回答了问题，两周后修回，第二个reviewer也几乎同意，再让加几篇参考文献，编辑给了小修，一天后修回，一周左右接收！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fe1d1672319, createdName=1de14753m02(暂无匿称), createdTime=Mon Aug 05 00:00:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106011, encodeId=6ca72106011ad, content=偏重的研究方向：临床结合基础研究 经验分享： Under peer review两个月以后decision pending然后变成 in review是啥意思, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=水逆退散～, createdTime=Wed Dec 14 14:36:16 CST 2022, time=2022-12-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1088924, encodeId=b0f6108892482, content=什么是MS?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088923, encodeId=d61f108892342, content=投稿时候是否一定要提供每个作者的ORCIDID?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2021-02-28 12362864m67暂无昵称

稿件号0076，under peer review40天了还没消息，有必要催一下不，好捉急

97 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=944268, encodeId=a40894426863, content=稿件号0076，under peer review40天了还没消息，有必要催一下不，好捉急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210411/da80771de7994056b41a9cf7d83c2962/5ab66ed7d0ad45638a7838a3990b1120.jpg, createdBy=97072405099, createdName=12362864m67暂无昵称, createdTime=Sun Feb 28 20:51:46 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=979002, encodeId=2c789e9002f2, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：前后经历拒稿重投，一审大修，一共160天，刚接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210411/da80771de7994056b41a9cf7d83c2962/5ab66ed7d0ad45638a7838a3990b1120.jpg, createdBy=97072405099, createdName=12362864m67暂无昵称, createdTime=Fri Jul 02 13:54:12 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903765, encodeId=fab8903e6588, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：Current Stage: In review，具体的stage: manuscript rejected，然后紧接着是in review，under peer revie一共50天，邮件目前还没发来，我想看看具体意见，一般要等几天啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10831618640, createdName=ygbn2003, createdTime=Tue Dec 01 09:15:47 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567729, encodeId=d14d56e729ba, content=后来送审没？zcxzcx 2016-04-30 21:05:00 发表: 我投了一篇，两天后给邮件说送同行评议，4周内给答复。5天后又成了副编辑审稿了。估计没有送审。不可能中的了。, beContent=zcxzcx 2016-04-30 21:05:00 发表: 我投了一篇，两天后给邮件说送同行评议，4周内给答复。5天后又成了副编辑审稿了。估计没有送审。不可能中的了。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22631703971, createdName=锦参, createdTime=Thu Mar 07 00:00:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801681, encodeId=d39580168137, content=投稿命中率:50.0 经验分享：杂志编辑友好，审稿人认真专业，一审周期1月，大修，二审周期1月，小修，三审半月，修回后接受，可选择OA或不OA。临床+基础+动物实验都有，同行评审的很专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=634, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12881707574, createdName=龙行, createdTime=Wed Jul 08 00:24:01 CST 2020, time=2020-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800767, encodeId=8ee1800e674f, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：看到大家都说很难中，就心惊胆战的投了稿。第一次投稿时，由于其中一个审稿人列出了很多意见，编辑让修改后重投，重新投稿后还是原来的审稿人审的，9天就审完了，给了小修意见，修改后再提交直接接收，一周内见刊。杂志对临床标本和动物造模的方法学要求很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/956562A6F0D877680D4FFBCDFE6C84CF/100, createdBy=40fb1970149, createdName=12.17, createdTime=Wed Jul 01 14:18:04 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574450, encodeId=91ae5e44501b, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：投过去十天左右送审，二十多天一审结束，一个reviewer几乎同意，一个大修，编辑给了大修意见，好多没法补实验，诚恳的回答了问题，两周后修回，第二个reviewer也几乎同意，再让加几篇参考文献，编辑给了小修，一天后修回，一周左右接收！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fe1d1672319, createdName=1de14753m02(暂无匿称), createdTime=Mon Aug 05 00:00:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106011, encodeId=6ca72106011ad, content=偏重的研究方向：临床结合基础研究 经验分享： Under peer review两个月以后decision pending然后变成 in review是啥意思, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=水逆退散～, createdTime=Wed Dec 14 14:36:16 CST 2022, time=2022-12-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1088924, encodeId=b0f6108892482, content=什么是MS?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088923, encodeId=d61f108892342, content=投稿时候是否一定要提供每个作者的ORCIDID?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2021-07-02 12362864m67暂无昵称

审稿速度:2.0 | 投稿命中率:25.0
经验分享：前后经历拒稿重投，一审大修，一共160天，刚接收。

85 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=944268, encodeId=a40894426863, content=稿件号0076，under peer review40天了还没消息，有必要催一下不，好捉急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210411/da80771de7994056b41a9cf7d83c2962/5ab66ed7d0ad45638a7838a3990b1120.jpg, createdBy=97072405099, createdName=12362864m67暂无昵称, createdTime=Sun Feb 28 20:51:46 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=979002, encodeId=2c789e9002f2, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：前后经历拒稿重投，一审大修，一共160天，刚接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210411/da80771de7994056b41a9cf7d83c2962/5ab66ed7d0ad45638a7838a3990b1120.jpg, createdBy=97072405099, createdName=12362864m67暂无昵称, createdTime=Fri Jul 02 13:54:12 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903765, encodeId=fab8903e6588, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：Current Stage: In review，具体的stage: manuscript rejected，然后紧接着是in review，under peer revie一共50天，邮件目前还没发来，我想看看具体意见，一般要等几天啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10831618640, createdName=ygbn2003, createdTime=Tue Dec 01 09:15:47 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567729, encodeId=d14d56e729ba, content=后来送审没？zcxzcx 2016-04-30 21:05:00 发表: 我投了一篇，两天后给邮件说送同行评议，4周内给答复。5天后又成了副编辑审稿了。估计没有送审。不可能中的了。, beContent=zcxzcx 2016-04-30 21:05:00 发表: 我投了一篇，两天后给邮件说送同行评议，4周内给答复。5天后又成了副编辑审稿了。估计没有送审。不可能中的了。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22631703971, createdName=锦参, createdTime=Thu Mar 07 00:00:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801681, encodeId=d39580168137, content=投稿命中率:50.0 经验分享：杂志编辑友好，审稿人认真专业，一审周期1月，大修，二审周期1月，小修，三审半月，修回后接受，可选择OA或不OA。临床+基础+动物实验都有，同行评审的很专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=634, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12881707574, createdName=龙行, createdTime=Wed Jul 08 00:24:01 CST 2020, time=2020-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800767, encodeId=8ee1800e674f, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：看到大家都说很难中，就心惊胆战的投了稿。第一次投稿时，由于其中一个审稿人列出了很多意见，编辑让修改后重投，重新投稿后还是原来的审稿人审的，9天就审完了，给了小修意见，修改后再提交直接接收，一周内见刊。杂志对临床标本和动物造模的方法学要求很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/956562A6F0D877680D4FFBCDFE6C84CF/100, createdBy=40fb1970149, createdName=12.17, createdTime=Wed Jul 01 14:18:04 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574450, encodeId=91ae5e44501b, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：投过去十天左右送审，二十多天一审结束，一个reviewer几乎同意，一个大修，编辑给了大修意见，好多没法补实验，诚恳的回答了问题，两周后修回，第二个reviewer也几乎同意，再让加几篇参考文献，编辑给了小修，一天后修回，一周左右接收！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fe1d1672319, createdName=1de14753m02(暂无匿称), createdTime=Mon Aug 05 00:00:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106011, encodeId=6ca72106011ad, content=偏重的研究方向：临床结合基础研究 经验分享： Under peer review两个月以后decision pending然后变成 in review是啥意思, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=水逆退散～, createdTime=Wed Dec 14 14:36:16 CST 2022, time=2022-12-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1088924, encodeId=b0f6108892482, content=什么是MS?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088923, encodeId=d61f108892342, content=投稿时候是否一定要提供每个作者的ORCIDID?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2020-12-01 ygbn2003

审稿速度:2.0 | 投稿命中率:25.0
经验分享：Current Stage: In review，具体的stage: manuscript rejected，然后紧接着是in review，under peer revie一共50天，邮件目前还没发来，我想看看具体意见，一般要等几天啊

118 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=944268, encodeId=a40894426863, content=稿件号0076，under peer review40天了还没消息，有必要催一下不，好捉急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210411/da80771de7994056b41a9cf7d83c2962/5ab66ed7d0ad45638a7838a3990b1120.jpg, createdBy=97072405099, createdName=12362864m67暂无昵称, createdTime=Sun Feb 28 20:51:46 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=979002, encodeId=2c789e9002f2, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：前后经历拒稿重投，一审大修，一共160天，刚接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210411/da80771de7994056b41a9cf7d83c2962/5ab66ed7d0ad45638a7838a3990b1120.jpg, createdBy=97072405099, createdName=12362864m67暂无昵称, createdTime=Fri Jul 02 13:54:12 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903765, encodeId=fab8903e6588, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：Current Stage: In review，具体的stage: manuscript rejected，然后紧接着是in review，under peer revie一共50天，邮件目前还没发来，我想看看具体意见，一般要等几天啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10831618640, createdName=ygbn2003, createdTime=Tue Dec 01 09:15:47 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567729, encodeId=d14d56e729ba, content=后来送审没？zcxzcx 2016-04-30 21:05:00 发表: 我投了一篇，两天后给邮件说送同行评议，4周内给答复。5天后又成了副编辑审稿了。估计没有送审。不可能中的了。, beContent=zcxzcx 2016-04-30 21:05:00 发表: 我投了一篇，两天后给邮件说送同行评议，4周内给答复。5天后又成了副编辑审稿了。估计没有送审。不可能中的了。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22631703971, createdName=锦参, createdTime=Thu Mar 07 00:00:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801681, encodeId=d39580168137, content=投稿命中率:50.0 经验分享：杂志编辑友好，审稿人认真专业，一审周期1月，大修，二审周期1月，小修，三审半月，修回后接受，可选择OA或不OA。临床+基础+动物实验都有，同行评审的很专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=634, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12881707574, createdName=龙行, createdTime=Wed Jul 08 00:24:01 CST 2020, time=2020-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800767, encodeId=8ee1800e674f, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：看到大家都说很难中，就心惊胆战的投了稿。第一次投稿时，由于其中一个审稿人列出了很多意见，编辑让修改后重投，重新投稿后还是原来的审稿人审的，9天就审完了，给了小修意见，修改后再提交直接接收，一周内见刊。杂志对临床标本和动物造模的方法学要求很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/956562A6F0D877680D4FFBCDFE6C84CF/100, createdBy=40fb1970149, createdName=12.17, createdTime=Wed Jul 01 14:18:04 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574450, encodeId=91ae5e44501b, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：投过去十天左右送审，二十多天一审结束，一个reviewer几乎同意，一个大修，编辑给了大修意见，好多没法补实验，诚恳的回答了问题，两周后修回，第二个reviewer也几乎同意，再让加几篇参考文献，编辑给了小修，一天后修回，一周左右接收！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fe1d1672319, createdName=1de14753m02(暂无匿称), createdTime=Mon Aug 05 00:00:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106011, encodeId=6ca72106011ad, content=偏重的研究方向：临床结合基础研究 经验分享： Under peer review两个月以后decision pending然后变成 in review是啥意思, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=水逆退散～, createdTime=Wed Dec 14 14:36:16 CST 2022, time=2022-12-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1088924, encodeId=b0f6108892482, content=什么是MS?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088923, encodeId=d61f108892342, content=投稿时候是否一定要提供每个作者的ORCIDID?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2019-03-07 锦参

后来送审没？zcxzcx 2016-04-30 21:05:00 发表:
我投了一篇，两天后给邮件说送同行评议，4周内给答复。5天后又成了副编辑审稿了。估计没有送审。不可能中的了。

zcxzcx 2016-04-30 21:05:00 发表: 我投了一篇，两天后给邮件说送同行评议，4周内给答复。5天后又成了副编辑审稿了。估计没有送审。不可能中的了。

211 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=944268, encodeId=a40894426863, content=稿件号0076，under peer review40天了还没消息，有必要催一下不，好捉急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210411/da80771de7994056b41a9cf7d83c2962/5ab66ed7d0ad45638a7838a3990b1120.jpg, createdBy=97072405099, createdName=12362864m67暂无昵称, createdTime=Sun Feb 28 20:51:46 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=979002, encodeId=2c789e9002f2, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：前后经历拒稿重投，一审大修，一共160天，刚接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210411/da80771de7994056b41a9cf7d83c2962/5ab66ed7d0ad45638a7838a3990b1120.jpg, createdBy=97072405099, createdName=12362864m67暂无昵称, createdTime=Fri Jul 02 13:54:12 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903765, encodeId=fab8903e6588, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：Current Stage: In review，具体的stage: manuscript rejected，然后紧接着是in review，under peer revie一共50天，邮件目前还没发来，我想看看具体意见，一般要等几天啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10831618640, createdName=ygbn2003, createdTime=Tue Dec 01 09:15:47 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567729, encodeId=d14d56e729ba, content=后来送审没？zcxzcx 2016-04-30 21:05:00 发表: 我投了一篇，两天后给邮件说送同行评议，4周内给答复。5天后又成了副编辑审稿了。估计没有送审。不可能中的了。, beContent=zcxzcx 2016-04-30 21:05:00 发表: 我投了一篇，两天后给邮件说送同行评议，4周内给答复。5天后又成了副编辑审稿了。估计没有送审。不可能中的了。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22631703971, createdName=锦参, createdTime=Thu Mar 07 00:00:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801681, encodeId=d39580168137, content=投稿命中率:50.0 经验分享：杂志编辑友好，审稿人认真专业，一审周期1月，大修，二审周期1月，小修，三审半月，修回后接受，可选择OA或不OA。临床+基础+动物实验都有，同行评审的很专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=634, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12881707574, createdName=龙行, createdTime=Wed Jul 08 00:24:01 CST 2020, time=2020-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800767, encodeId=8ee1800e674f, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：看到大家都说很难中，就心惊胆战的投了稿。第一次投稿时，由于其中一个审稿人列出了很多意见，编辑让修改后重投，重新投稿后还是原来的审稿人审的，9天就审完了，给了小修意见，修改后再提交直接接收，一周内见刊。杂志对临床标本和动物造模的方法学要求很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/956562A6F0D877680D4FFBCDFE6C84CF/100, createdBy=40fb1970149, createdName=12.17, createdTime=Wed Jul 01 14:18:04 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574450, encodeId=91ae5e44501b, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：投过去十天左右送审，二十多天一审结束，一个reviewer几乎同意，一个大修，编辑给了大修意见，好多没法补实验，诚恳的回答了问题，两周后修回，第二个reviewer也几乎同意，再让加几篇参考文献，编辑给了小修，一天后修回，一周左右接收！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fe1d1672319, createdName=1de14753m02(暂无匿称), createdTime=Mon Aug 05 00:00:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106011, encodeId=6ca72106011ad, content=偏重的研究方向：临床结合基础研究 经验分享： Under peer review两个月以后decision pending然后变成 in review是啥意思, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=水逆退散～, createdTime=Wed Dec 14 14:36:16 CST 2022, time=2022-12-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1088924, encodeId=b0f6108892482, content=什么是MS?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088923, encodeId=d61f108892342, content=投稿时候是否一定要提供每个作者的ORCIDID?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2020-07-08 龙行

投稿命中率:50.0
经验分享：杂志编辑友好，审稿人认真专业，一审周期1月，大修，二审周期1月，小修，三审半月，修回后接受，可选择OA或不OA。临床+基础+动物实验都有，同行评审的很专业。

634 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=944268, encodeId=a40894426863, content=稿件号0076，under peer review40天了还没消息，有必要催一下不，好捉急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210411/da80771de7994056b41a9cf7d83c2962/5ab66ed7d0ad45638a7838a3990b1120.jpg, createdBy=97072405099, createdName=12362864m67暂无昵称, createdTime=Sun Feb 28 20:51:46 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=979002, encodeId=2c789e9002f2, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：前后经历拒稿重投，一审大修，一共160天，刚接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210411/da80771de7994056b41a9cf7d83c2962/5ab66ed7d0ad45638a7838a3990b1120.jpg, createdBy=97072405099, createdName=12362864m67暂无昵称, createdTime=Fri Jul 02 13:54:12 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903765, encodeId=fab8903e6588, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：Current Stage: In review，具体的stage: manuscript rejected，然后紧接着是in review，under peer revie一共50天，邮件目前还没发来，我想看看具体意见，一般要等几天啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10831618640, createdName=ygbn2003, createdTime=Tue Dec 01 09:15:47 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567729, encodeId=d14d56e729ba, content=后来送审没？zcxzcx 2016-04-30 21:05:00 发表: 我投了一篇，两天后给邮件说送同行评议，4周内给答复。5天后又成了副编辑审稿了。估计没有送审。不可能中的了。, beContent=zcxzcx 2016-04-30 21:05:00 发表: 我投了一篇，两天后给邮件说送同行评议，4周内给答复。5天后又成了副编辑审稿了。估计没有送审。不可能中的了。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22631703971, createdName=锦参, createdTime=Thu Mar 07 00:00:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801681, encodeId=d39580168137, content=投稿命中率:50.0 经验分享：杂志编辑友好，审稿人认真专业，一审周期1月，大修，二审周期1月，小修，三审半月，修回后接受，可选择OA或不OA。临床+基础+动物实验都有，同行评审的很专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=634, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12881707574, createdName=龙行, createdTime=Wed Jul 08 00:24:01 CST 2020, time=2020-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800767, encodeId=8ee1800e674f, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：看到大家都说很难中，就心惊胆战的投了稿。第一次投稿时，由于其中一个审稿人列出了很多意见，编辑让修改后重投，重新投稿后还是原来的审稿人审的，9天就审完了，给了小修意见，修改后再提交直接接收，一周内见刊。杂志对临床标本和动物造模的方法学要求很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/956562A6F0D877680D4FFBCDFE6C84CF/100, createdBy=40fb1970149, createdName=12.17, createdTime=Wed Jul 01 14:18:04 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574450, encodeId=91ae5e44501b, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：投过去十天左右送审，二十多天一审结束，一个reviewer几乎同意，一个大修，编辑给了大修意见，好多没法补实验，诚恳的回答了问题，两周后修回，第二个reviewer也几乎同意，再让加几篇参考文献，编辑给了小修，一天后修回，一周左右接收！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fe1d1672319, createdName=1de14753m02(暂无匿称), createdTime=Mon Aug 05 00:00:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106011, encodeId=6ca72106011ad, content=偏重的研究方向：临床结合基础研究 经验分享： Under peer review两个月以后decision pending然后变成 in review是啥意思, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=水逆退散～, createdTime=Wed Dec 14 14:36:16 CST 2022, time=2022-12-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1088924, encodeId=b0f6108892482, content=什么是MS?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088923, encodeId=d61f108892342, content=投稿时候是否一定要提供每个作者的ORCIDID?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2020-07-01 12.17

审稿速度:1.0 | 投稿命中率:50.0
经验分享：看到大家都说很难中，就心惊胆战的投了稿。第一次投稿时，由于其中一个审稿人列出了很多意见，编辑让修改后重投，重新投稿后还是原来的审稿人审的，9天就审完了，给了小修意见，修改后再提交直接接收，一周内见刊。杂志对临床标本和动物造模的方法学要求很高。

138 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=944268, encodeId=a40894426863, content=稿件号0076，under peer review40天了还没消息，有必要催一下不，好捉急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210411/da80771de7994056b41a9cf7d83c2962/5ab66ed7d0ad45638a7838a3990b1120.jpg, createdBy=97072405099, createdName=12362864m67暂无昵称, createdTime=Sun Feb 28 20:51:46 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=979002, encodeId=2c789e9002f2, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：前后经历拒稿重投，一审大修，一共160天，刚接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210411/da80771de7994056b41a9cf7d83c2962/5ab66ed7d0ad45638a7838a3990b1120.jpg, createdBy=97072405099, createdName=12362864m67暂无昵称, createdTime=Fri Jul 02 13:54:12 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903765, encodeId=fab8903e6588, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：Current Stage: In review，具体的stage: manuscript rejected，然后紧接着是in review，under peer revie一共50天，邮件目前还没发来，我想看看具体意见，一般要等几天啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10831618640, createdName=ygbn2003, createdTime=Tue Dec 01 09:15:47 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567729, encodeId=d14d56e729ba, content=后来送审没？zcxzcx 2016-04-30 21:05:00 发表: 我投了一篇，两天后给邮件说送同行评议，4周内给答复。5天后又成了副编辑审稿了。估计没有送审。不可能中的了。, beContent=zcxzcx 2016-04-30 21:05:00 发表: 我投了一篇，两天后给邮件说送同行评议，4周内给答复。5天后又成了副编辑审稿了。估计没有送审。不可能中的了。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22631703971, createdName=锦参, createdTime=Thu Mar 07 00:00:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801681, encodeId=d39580168137, content=投稿命中率:50.0 经验分享：杂志编辑友好，审稿人认真专业，一审周期1月，大修，二审周期1月，小修，三审半月，修回后接受，可选择OA或不OA。临床+基础+动物实验都有，同行评审的很专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=634, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12881707574, createdName=龙行, createdTime=Wed Jul 08 00:24:01 CST 2020, time=2020-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800767, encodeId=8ee1800e674f, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：看到大家都说很难中，就心惊胆战的投了稿。第一次投稿时，由于其中一个审稿人列出了很多意见，编辑让修改后重投，重新投稿后还是原来的审稿人审的，9天就审完了，给了小修意见，修改后再提交直接接收，一周内见刊。杂志对临床标本和动物造模的方法学要求很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/956562A6F0D877680D4FFBCDFE6C84CF/100, createdBy=40fb1970149, createdName=12.17, createdTime=Wed Jul 01 14:18:04 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574450, encodeId=91ae5e44501b, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：投过去十天左右送审，二十多天一审结束，一个reviewer几乎同意，一个大修，编辑给了大修意见，好多没法补实验，诚恳的回答了问题，两周后修回，第二个reviewer也几乎同意，再让加几篇参考文献，编辑给了小修，一天后修回，一周左右接收！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fe1d1672319, createdName=1de14753m02(暂无匿称), createdTime=Mon Aug 05 00:00:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106011, encodeId=6ca72106011ad, content=偏重的研究方向：临床结合基础研究 经验分享： Under peer review两个月以后decision pending然后变成 in review是啥意思, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=水逆退散～, createdTime=Wed Dec 14 14:36:16 CST 2022, time=2022-12-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1088924, encodeId=b0f6108892482, content=什么是MS?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088923, encodeId=d61f108892342, content=投稿时候是否一定要提供每个作者的ORCIDID?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2019-08-05 1de14753m02(暂无匿称)

审稿速度:1.0 | 投稿命中率:25.0
经验分享：投过去十天左右送审，二十多天一审结束，一个reviewer几乎同意，一个大修，编辑给了大修意见，好多没法补实验，诚恳的回答了问题，两周后修回，第二个reviewer也几乎同意，再让加几篇参考文献，编辑给了小修，一天后修回，一周左右接收！

176 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=944268, encodeId=a40894426863, content=稿件号0076，under peer review40天了还没消息，有必要催一下不，好捉急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210411/da80771de7994056b41a9cf7d83c2962/5ab66ed7d0ad45638a7838a3990b1120.jpg, createdBy=97072405099, createdName=12362864m67暂无昵称, createdTime=Sun Feb 28 20:51:46 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=979002, encodeId=2c789e9002f2, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：前后经历拒稿重投，一审大修，一共160天，刚接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210411/da80771de7994056b41a9cf7d83c2962/5ab66ed7d0ad45638a7838a3990b1120.jpg, createdBy=97072405099, createdName=12362864m67暂无昵称, createdTime=Fri Jul 02 13:54:12 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903765, encodeId=fab8903e6588, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：Current Stage: In review，具体的stage: manuscript rejected，然后紧接着是in review，under peer revie一共50天，邮件目前还没发来，我想看看具体意见，一般要等几天啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10831618640, createdName=ygbn2003, createdTime=Tue Dec 01 09:15:47 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567729, encodeId=d14d56e729ba, content=后来送审没？zcxzcx 2016-04-30 21:05:00 发表: 我投了一篇，两天后给邮件说送同行评议，4周内给答复。5天后又成了副编辑审稿了。估计没有送审。不可能中的了。, beContent=zcxzcx 2016-04-30 21:05:00 发表: 我投了一篇，两天后给邮件说送同行评议，4周内给答复。5天后又成了副编辑审稿了。估计没有送审。不可能中的了。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22631703971, createdName=锦参, createdTime=Thu Mar 07 00:00:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801681, encodeId=d39580168137, content=投稿命中率:50.0 经验分享：杂志编辑友好，审稿人认真专业，一审周期1月，大修，二审周期1月，小修，三审半月，修回后接受，可选择OA或不OA。临床+基础+动物实验都有，同行评审的很专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=634, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12881707574, createdName=龙行, createdTime=Wed Jul 08 00:24:01 CST 2020, time=2020-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800767, encodeId=8ee1800e674f, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：看到大家都说很难中，就心惊胆战的投了稿。第一次投稿时，由于其中一个审稿人列出了很多意见，编辑让修改后重投，重新投稿后还是原来的审稿人审的，9天就审完了，给了小修意见，修改后再提交直接接收，一周内见刊。杂志对临床标本和动物造模的方法学要求很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/956562A6F0D877680D4FFBCDFE6C84CF/100, createdBy=40fb1970149, createdName=12.17, createdTime=Wed Jul 01 14:18:04 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574450, encodeId=91ae5e44501b, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：投过去十天左右送审，二十多天一审结束，一个reviewer几乎同意，一个大修，编辑给了大修意见，好多没法补实验，诚恳的回答了问题，两周后修回，第二个reviewer也几乎同意，再让加几篇参考文献，编辑给了小修，一天后修回，一周左右接收！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fe1d1672319, createdName=1de14753m02(暂无匿称), createdTime=Mon Aug 05 00:00:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106011, encodeId=6ca72106011ad, content=偏重的研究方向：临床结合基础研究 经验分享： Under peer review两个月以后decision pending然后变成 in review是啥意思, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=水逆退散～, createdTime=Wed Dec 14 14:36:16 CST 2022, time=2022-12-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1088924, encodeId=b0f6108892482, content=什么是MS?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088923, encodeId=d61f108892342, content=投稿时候是否一定要提供每个作者的ORCIDID?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2022-12-14 水逆退散～来自广西

偏重的研究方向：临床结合基础研究
经验分享： Under peer review两个月以后decision pending然后变成 in review是啥意思

42 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=944268, encodeId=a40894426863, content=稿件号0076，under peer review40天了还没消息，有必要催一下不，好捉急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210411/da80771de7994056b41a9cf7d83c2962/5ab66ed7d0ad45638a7838a3990b1120.jpg, createdBy=97072405099, createdName=12362864m67暂无昵称, createdTime=Sun Feb 28 20:51:46 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=979002, encodeId=2c789e9002f2, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：前后经历拒稿重投，一审大修，一共160天，刚接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210411/da80771de7994056b41a9cf7d83c2962/5ab66ed7d0ad45638a7838a3990b1120.jpg, createdBy=97072405099, createdName=12362864m67暂无昵称, createdTime=Fri Jul 02 13:54:12 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903765, encodeId=fab8903e6588, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：Current Stage: In review，具体的stage: manuscript rejected，然后紧接着是in review，under peer revie一共50天，邮件目前还没发来，我想看看具体意见，一般要等几天啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10831618640, createdName=ygbn2003, createdTime=Tue Dec 01 09:15:47 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567729, encodeId=d14d56e729ba, content=后来送审没？zcxzcx 2016-04-30 21:05:00 发表: 我投了一篇，两天后给邮件说送同行评议，4周内给答复。5天后又成了副编辑审稿了。估计没有送审。不可能中的了。, beContent=zcxzcx 2016-04-30 21:05:00 发表: 我投了一篇，两天后给邮件说送同行评议，4周内给答复。5天后又成了副编辑审稿了。估计没有送审。不可能中的了。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22631703971, createdName=锦参, createdTime=Thu Mar 07 00:00:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801681, encodeId=d39580168137, content=投稿命中率:50.0 经验分享：杂志编辑友好，审稿人认真专业，一审周期1月，大修，二审周期1月，小修，三审半月，修回后接受，可选择OA或不OA。临床+基础+动物实验都有，同行评审的很专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=634, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12881707574, createdName=龙行, createdTime=Wed Jul 08 00:24:01 CST 2020, time=2020-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800767, encodeId=8ee1800e674f, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：看到大家都说很难中，就心惊胆战的投了稿。第一次投稿时，由于其中一个审稿人列出了很多意见，编辑让修改后重投，重新投稿后还是原来的审稿人审的，9天就审完了，给了小修意见，修改后再提交直接接收，一周内见刊。杂志对临床标本和动物造模的方法学要求很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/956562A6F0D877680D4FFBCDFE6C84CF/100, createdBy=40fb1970149, createdName=12.17, createdTime=Wed Jul 01 14:18:04 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574450, encodeId=91ae5e44501b, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：投过去十天左右送审，二十多天一审结束，一个reviewer几乎同意，一个大修，编辑给了大修意见，好多没法补实验，诚恳的回答了问题，两周后修回，第二个reviewer也几乎同意，再让加几篇参考文献，编辑给了小修，一天后修回，一周左右接收！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fe1d1672319, createdName=1de14753m02(暂无匿称), createdTime=Mon Aug 05 00:00:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106011, encodeId=6ca72106011ad, content=偏重的研究方向：临床结合基础研究 经验分享： Under peer review两个月以后decision pending然后变成 in review是啥意思, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=水逆退散～, createdTime=Wed Dec 14 14:36:16 CST 2022, time=2022-12-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1088924, encodeId=b0f6108892482, content=什么是MS?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088923, encodeId=d61f108892342, content=投稿时候是否一定要提供每个作者的ORCIDID?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2021-12-27 Mia

什么是MS?

77 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=944268, encodeId=a40894426863, content=稿件号0076，under peer review40天了还没消息，有必要催一下不，好捉急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210411/da80771de7994056b41a9cf7d83c2962/5ab66ed7d0ad45638a7838a3990b1120.jpg, createdBy=97072405099, createdName=12362864m67暂无昵称, createdTime=Sun Feb 28 20:51:46 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=979002, encodeId=2c789e9002f2, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：前后经历拒稿重投，一审大修，一共160天，刚接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210411/da80771de7994056b41a9cf7d83c2962/5ab66ed7d0ad45638a7838a3990b1120.jpg, createdBy=97072405099, createdName=12362864m67暂无昵称, createdTime=Fri Jul 02 13:54:12 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903765, encodeId=fab8903e6588, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：Current Stage: In review，具体的stage: manuscript rejected，然后紧接着是in review，under peer revie一共50天，邮件目前还没发来，我想看看具体意见，一般要等几天啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10831618640, createdName=ygbn2003, createdTime=Tue Dec 01 09:15:47 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567729, encodeId=d14d56e729ba, content=后来送审没？zcxzcx 2016-04-30 21:05:00 发表: 我投了一篇，两天后给邮件说送同行评议，4周内给答复。5天后又成了副编辑审稿了。估计没有送审。不可能中的了。, beContent=zcxzcx 2016-04-30 21:05:00 发表: 我投了一篇，两天后给邮件说送同行评议，4周内给答复。5天后又成了副编辑审稿了。估计没有送审。不可能中的了。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22631703971, createdName=锦参, createdTime=Thu Mar 07 00:00:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801681, encodeId=d39580168137, content=投稿命中率:50.0 经验分享：杂志编辑友好，审稿人认真专业，一审周期1月，大修，二审周期1月，小修，三审半月，修回后接受，可选择OA或不OA。临床+基础+动物实验都有，同行评审的很专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=634, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12881707574, createdName=龙行, createdTime=Wed Jul 08 00:24:01 CST 2020, time=2020-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800767, encodeId=8ee1800e674f, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：看到大家都说很难中，就心惊胆战的投了稿。第一次投稿时，由于其中一个审稿人列出了很多意见，编辑让修改后重投，重新投稿后还是原来的审稿人审的，9天就审完了，给了小修意见，修改后再提交直接接收，一周内见刊。杂志对临床标本和动物造模的方法学要求很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/956562A6F0D877680D4FFBCDFE6C84CF/100, createdBy=40fb1970149, createdName=12.17, createdTime=Wed Jul 01 14:18:04 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574450, encodeId=91ae5e44501b, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：投过去十天左右送审，二十多天一审结束，一个reviewer几乎同意，一个大修，编辑给了大修意见，好多没法补实验，诚恳的回答了问题，两周后修回，第二个reviewer也几乎同意，再让加几篇参考文献，编辑给了小修，一天后修回，一周左右接收！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fe1d1672319, createdName=1de14753m02(暂无匿称), createdTime=Mon Aug 05 00:00:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106011, encodeId=6ca72106011ad, content=偏重的研究方向：临床结合基础研究 经验分享： Under peer review两个月以后decision pending然后变成 in review是啥意思, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=水逆退散～, createdTime=Wed Dec 14 14:36:16 CST 2022, time=2022-12-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1088924, encodeId=b0f6108892482, content=什么是MS?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088923, encodeId=d61f108892342, content=投稿时候是否一定要提供每个作者的ORCIDID?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2021-12-27 MS54455111222

投稿时候是否一定要提供每个作者的ORCIDID?

57 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务